GlassScriptPhysician profile
Maria Rose Vacha
NPI 1528420932
$1,640.59
in general payments reported to CMS, 2019-2025
26 companies · $742 in 2025
The $742 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.91 · 2021: $40.61 · 2022: $334 · 2023: $195 · 2024: $286 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.43 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Novo Nordisk INC | $253.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $182.72 | 2019-2025 | |
| Lilly USA, LLC | $155.28 | 2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $62.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $60.35 | 2025 | Airsupra |
| Boston Scientific Corporation | $57.40 | 2022-2024 | Watchman Flx |
| Astellas Pharma US INC | $50.18 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.17 | 2022-2024 | Xifaxan |
| Biogen, INC. | $45.84 | 2023-2025 | Spinraza, Zurzuvae |
| Amgen INC. | $30.57 | 2024-2025 | Evenity, Prolia |
| Medtronic, INC. | $29.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.46 | 2022-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $25.71 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $20.81 | 2025 | Opsumit, Uptravi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.55 | 2024 | |
| Neurelis, INC. | $18.23 | 2022 | |
| Dynavax Technologies Corporation | $17.91 | 2025 | Heplisav-B |
| Organon LLC | $17.64 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.44 | 2025 | Azmiro |
| Krystal Biotech INC | $17.39 | 2025 | Vyjuvek |
| Arbor Pharmaceuticals, INC. | $17.03 | 2021 | |
| Merck Sharp & Dohme LLC | $16.58 | 2025 | Rotateq, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $15.68 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $13.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $10.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Vacha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.